spacer
home > ebr > winter 2003 > drug discovery in the post-genomic era
PUBLICATIONS
European Biopharmaceutical Review

Drug Discovery in the Post-Genomic Era

2003 marked the completion of the human genome project and we now find ourselves in a post-genomic era, trying to understand and utilise a previously unimaginable amount of biological information. Scientists have the daunting task of finding new ways to use the human genome sequence for the benefit of humanity - to develop new drugs and to find better ways to combat disease.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Steve Lombardi, Vice President of Corporate Development at Affymetrix, Inc

Steve Lombardi is Vice President of Corporate Development at Affymetrix, Inc. He has made significant progress in moving early-stage, advanced technology out to customers. Prior to joining Affymetrix, Steve was Senior Vice President of Applications and Products for Applied Biosystems, managing strategic marketing and applications R&D. He earned his BA in Biology from Merrimack College.

spacer
Steve Lombardi
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Peli BioThermal showcase CoolPall™ Flex and industry leading solutions at Temperature Control and Logistics Conference

Peli BioThermal, the global name in temperature-controlled packaging, is exhibiting its industry leading shipper systems, including its innovative CoolPall™ Flex, at the 19th Annual Cool Chain Temperature Control and Logistics conference.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 
Industry Events

BioTrinity 2020

28-29 April 2020, Etc Venues, London

BioTrinity is a long-running and highly regarded two day life sciences conference that takes place in Central London from 28-29 April. BioTrinity focuses on partnering, investment and collaboration and aims to inspire growth and create opportunities for all who attend. The core delegate mix includes early-stage and emerging biotech, medtech and digital health companies, big pharma executives and life sciences investors.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement